Latest Insider Transactions at Cassava Sciences Inc (SAVA)
This section provides a real-time view of insider transactions for Cassava Sciences Inc (SAVA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CASSAVA SCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CASSAVA SCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
Sanford Robertson Director |
BUY
Bona fide gift
|
Indirect |
5,000
+50.0%
|
-
|
|
May 16
2024
|
Sanford Robertson Director |
SELL
Bona fide gift
|
Direct |
5,000
-0.52%
|
-
|
|
Apr 26
2024
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69,000
+6.73%
|
$1,518,000
$22.0 P/Share
|
|
Apr 23
2024
|
Richard Barry President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
176,085
+27.27%
|
$3,873,870
$22.0 P/Share
|
|
Apr 18
2024
|
James William Kupiec Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+27.27%
|
$33,000
$22.0 P/Share
|
|
Apr 17
2024
|
Eric Schoen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+6.58%
|
$33,000
$22.0 P/Share
|
|
Aug 23
2023
|
Sanford Robertson Director |
BUY
Open market or private purchase
|
Direct |
30,000
+3.27%
|
$510,000
$17.45 P/Share
|
|
Aug 22
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
16,571
+5.34%
|
$265,136
$16.65 P/Share
|
|
Aug 21
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
1,906
+0.68%
|
$30,496
$16.8 P/Share
|
|
Jun 12
2023
|
Patrick J Md Phd Scannon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$0
$0.95 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
47,723
-6.1%
|
$1,193,075
$25.25 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
71,428
+8.37%
|
$1,142,848
$16.87 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
9,545
-2.44%
|
$238,625
$25.25 P/Share
|
|
May 24
2023
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,285
+3.53%
|
$228,560
$16.87 P/Share
|
|
May 10
2023
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,284
+0.36%
|
$157,828
$17.64 P/Share
|
|
May 01
2023
|
Robert Z Gussin Director |
BUY
Payment of exercise price or tax liability
|
Direct |
7,077
+40.0%
|
$162,771
$23.34 P/Share
|
|
May 01
2023
|
Robert Z Gussin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,284
+17.95%
|
$157,828
$17.64 P/Share
|
|
Mar 07
2023
|
Michael J O Donnell Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,139
-24.22%
|
$128,475
$25.2 P/Share
|
|
Mar 07
2023
|
Michael J O Donnell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,142
+26.32%
|
$128,556
$18.13 P/Share
|
|
Mar 07
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
77,276
+21.94%
|
$1,931,900
$25.76 P/Share
|
|
Mar 06
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
11,565
+5.53%
|
$300,690
$26.13 P/Share
|
|
Oct 03
2022
|
Nadav Friedmann Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,376
+10.5%
|
$0
$0.95 P/Share
|
|
Sep 08
2022
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,802
+0.27%
|
$64,446
$23.59 P/Share
|
|
Aug 23
2022
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
36,159
+16.26%
|
$831,657
$23.79 P/Share
|
|
Aug 23
2022
|
James William Kupiec Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$60,000
$24.44 P/Share
|
|
Aug 12
2022
|
Sanford Robertson Director |
BUY
Open market or private purchase
|
Direct |
100,000
+8.89%
|
$2,000,000
$20.69 P/Share
|
|
Aug 12
2022
|
Eric Schoen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+11.21%
|
$47,500
$19.95 P/Share
|
|
Jun 06
2022
|
Remi Barbier President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
54,720
-6.65%
|
$1,477,440
$27.93 P/Share
|
|
Jun 06
2022
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,368
+7.36%
|
$1,503,464
$23.38 P/Share
|
|
May 27
2022
|
Nadav Friedmann Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,569
-13.29%
|
$638,794
$26.66 P/Share
|
|
May 27
2022
|
Nadav Friedmann Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,014
+12.61%
|
$644,322
$23.38 P/Share
|
|
Apr 25
2022
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
49,460
+5.99%
|
$395,680
$8.63 P/Share
|
|
Mar 29
2022
|
Robert Z Gussin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,024
-32.36%
|
$156,936
$39.98 P/Share
|
|
Mar 29
2022
|
Robert Z Gussin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,470
+25.52%
|
$156,870
$21.95 P/Share
|
|
Mar 25
2022
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,670
+0.5%
|
$93,400
$20.3 P/Share
|
|
Sep 15
2021
|
Robert Z Gussin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,746
-26.02%
|
$75,078
$43.92 P/Share
|
|
Sep 15
2021
|
Robert Z Gussin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,801
+29.45%
|
$75,627
$27.37 P/Share
|
|
Jul 20
2021
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,801
+0.85%
|
$56,020
$20.23 P/Share
|
|
May 27
2021
|
Remi Barbier President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
53,965
-4.76%
|
$2,968,075
$55.6 P/Share
|
|
May 27
2021
|
Remi Barbier President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
56,030
+4.7%
|
$2,969,590
$53.55 P/Share
|
|
Mar 30
2021
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,472
+0.41%
|
$283,936
$38.19 P/Share
|
|
Mar 17
2021
|
Nadav Friedmann Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,996
-25.96%
|
$1,487,752
$62.52 P/Share
|
|
Mar 17
2021
|
Nadav Friedmann Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,015
+23.26%
|
$1,484,795
$53.55 P/Share
|
|
Mar 16
2021
|
Michael J O Donnell Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,387
-47.39%
|
$228,124
$52.16 P/Share
|
|
Mar 16
2021
|
Michael J O Donnell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,669
+33.53%
|
$228,781
$49.0 P/Share
|
|
Oct 03
2018
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Oct 03
2018
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
512,660
-23.69%
|
$512,660
$1.31 P/Share
|
|
Aug 20
2018
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Aug 20
2018
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
8,000
-0.37%
|
$0
$0.91 P/Share
|
|
Aug 17
2018
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|